Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07204977) titled 'Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)' on Oct. 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Condition:
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Intervention:
Drug: Acamprosate calcium
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: October 15, 2025
Target Sample Size: 30
Countries of Recruitment:
United States
To know m...